-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compileriver
On June 14th, according to foreign media reports, Johnson & Johnson’s Imbruvica combined with Roche’s Genentech’s Venclexta (venetoclax) succeeded in a phase III GLOW study, which evaluated the combination therapy as a chronic disease in the elderly or in poor health.
The study conducted by Johnson & Johnson subsidiary Janssen compared Imbruvica+Venclexta combination therapy with chlorambucil + obinutuzumab (Clb+O) in this patient population
Imbruvica and Venclexta have complementary mechanisms of action
GLOW's data shows that the oral combination therapy of Imbruvica and venetoclax once a day for a fixed duration is better than standard chemotherapy and immunotherapy.
In addition to the GLOW phase III study, Janssen also announced that the phase III MAIA study evaluated the overall survival (OS) of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd) over the use of Rd alone
Reference source: Janssen Hits Two Phase III Marks in Hematology Presentations at EHA